Expired activity
Please go to the PowerPak homepage and select a course.

Managing Adverse Effects with Multimodal Cancer Therapy: Pharmacists Perspectives

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported an educational grant from Eisai and Merck & Co., LLC.


Lisa Holle, PharmD, BCOP, FHOPA
Associate Clinical Professor
University of Connecticut
School of Pharmacy
Storrs, CT

Ali McBride PharmD, MS, BCPS, BCOP
Clinical Coordinator, Department of Pharmacy
The University of Arizona Cancer Center
Clinical Assistant Professor, Department of Pharmacy Practice
The University of Arizona, College of Pharmacy
Tucson, AZ


Lisa Holle, PharmD, BCOP, FHOPA, has disclosed that she has no relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity.

Ali McBride PharmD, MS, BCPS, BCOP has discloses that he has served on the Merck & Co. speaker's bureau.

Susanne Batesko, RN, BSN, Robin Soboti, R.Ph, and Susan R. Grady, MSN, RN-BC, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN:  0430-0000-19-096-H01-P
Credits: 2.0 hours (0.20 ceu)

Type of Activity: Application
Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 120 minutes


December 31, 2019


September 25, 2020 (see updates at the end of the monograph)


December 31, 2020


This activity has been designed to meet the needs of oncology, health-system and specialty pharmacists nationwide.


During the period December 31, 2019 through December 31, 2020, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


The goal of this educational activity is to inform and educate oncology, health-system and specialty pharmacists about emerging combination cancer therapies involving contemporary and conventional therapies, and identification and management of AEs arising from the use of these novel combinations to optimize patient care and outcomes.


Upon completion of this program, participants should be better able to:

  • Discuss the rationale for combination therapy in cancer care   
  • Compare and contrast adverse effects related to the use of targeted therapies, immunotherapy, and cytotoxic chemotherapy
  • Describe the impact on adverse effects when targeted therapies are combined with checkpoint inhibitors or cytotoxic chemotherapy
  • Formulate effective strategies to monitor for and manage adverse events in patients receiving targeted therapies in combination with chemotherapy or immunotherapy


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer:

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Eisai or Merck & Co., LLC. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.